Performance of commercially available enzyme Immunoassays for detection of antibodies against herpes simplex virus type 2 in African populations
Performance of commercially available enzyme Immunoassays for detection of antibodies against herpes simplex virus type 2 in African populations
复制标题
DOI：
10.1128/jcm.42.7.2961-2965.2004
复制
发表时间：
2004-07-01
影响因子：
9.4
通讯作者：
Hayes, RJ
中科院分区：
文献类型：
--
作者：
Van Dyck, E;Buvé, A;Hayes, RJ
在北美和欧洲，有关酶免疫测定法（EIAs）用于检测单纯疱疹病毒2型（HSV - 2）感染的性能数据不断积累，但对于它们在其他人群中的性能却知之甚少。用来自撒哈拉以南非洲的330份血清样本对9种检测试剂盒进行了评估。首先将这些检测与单克隆抗体（MAb）EIA（英国伦敦中央公共卫生实验室）进行比较。在单克隆抗体EIA以及与单克隆抗体EIA相比表现最佳的三种检测中结果不一致的样本，通过蛋白质印迹法（美国西雅图华盛顿大学）进行检测。还对一致样本进行了随机抽样检测，并考虑到这种抽样策略，计算了不同检测的敏感性和特异性。这些检测的敏感性范围为86%到100%；特异性范围为47%到99%。表现最佳的检测是Gull Premier EIA（敏感性86.3%；特异性97.6%）、Kalon Biological（敏感性92.3%；特异性97.7%）以及Biokit（敏感性86.7%；特异性92.6%）检测。不能假定在工业化国家用于检测HSV - 2感染表现良好的酶免疫测定法在其他人群中也会有同样良好的表现。
Data are accumulating on the performance of enzyme immunoassays (EIAs) for the detection of herpes simplex virus type 2 (HSV-2) infection in North America and Europe, but little is known about their performance in other populations. Nine test kits were evaluated with 330 serum samples from sub-Saharan Africa. The tests were first compared to the monoclonal antibody (MAII) EIA (Central Public Health Laboratory, London, United Kingdom). Samples that gave discordant results in the MAb EIA and in the three tests that performed best compared to the MAb EIA were tested by Western blotting (University of Washington, Seattle). A random sample of concordant samples was also tested, and the sensitivities and specificities of the different tests were calculated, taking into account this sampling strategy. The sensitivities of the tests ranged from 86 to 100%; the specificities ranged from 47 to 99%. The tests that performed best were the Gull Premier EIA (sensitivity, 86.3%; specificity, 97.6%) and the Kalon Biological (sensitivity, 92.3%; specificity, 97.7%) and Biokit (sensitivity, 86.7%; specificity, 92.6%) tests. It cannot be assumed that enzyme immunoassays for the detection of HSV-2 infection that perform well in industrialized countries will perform equally well in other populations.